Rainer Spanagel
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from induced pluripotent stem cells with the 5-HT2A receptor agonist psilocin - the psychoactive metabolite of psilocybin. We analyzed how exposure to psilocin affects gene expression, neuronal morphology, synaptic markers and neuronal function. Psilocin provoked a 5-HT2A-R-mediated augmentation of BDNF abundance. Transcriptomic profiling identified gene expression signatures priming neurons to neuroplasticity. On a morphological level, psilocin induced enhanced neuronal complexity and increased expression of synaptic proteins, in particular in the postsynaptic-compartment. Consistently, we observed an increased excitability and enhanced synaptic network activity in neurons treated with psilocin. In conclusion, exposure of human neurons to psilocin might induce a state of enhanced neuronal plasticity which could explain why psilocin is beneficial in the treatment of neuropsychiatric disorders where synaptic dysfunctions are discussed.
Year:
2026
A shift away from goal-directed, model-based behavior is commonly viewed to characterize alcohol use disorder (AUD). Previous research, however, has failed to demonstrate differences between individuals with and without AUD regarding goal-directed control, operationalized as model-based behavior. Instead, findings suggest associations between model-based behavior and alcohol consumption patterns, but mechanistic insights into the link between model-based behavioral and neural signatures and longitudinal, real-life control over alcohol intake remain elusive. Here, we investigated whether experimentally assessed model-based behavior can prospectively predict intentional reduction of alcohol consumption in daily life. Therefore, we related behavioral and neural markers of model-based behavior during a sequential decision-making task in 67 participants with AUD (20 women) to long-term smartphone-based ecological momentary assessments of daily alcohol intake and weekly alcohol consumption intentions over a period of up to one year. Model-based behavior and its neural signatures in bilateral hippocampus and ventral striatum moderated how well individuals succeeded in aligning their alcohol consumption with their drinking intentions during the following year. Specifically, AUD participants with higher model-based behavior and associated stronger hippocampal and weaker ventral striatal learning signals exhibited enhanced capacity to intentionally reduce their alcohol consumption in everyday life. These findings provide evidence for the ecological validity of computational concepts of goal-directed behavior and suggest specific treatment targets for individually tailored interventions to regain control over alcohol use.
Year:
2025
Year:
2025
The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol deprivation effect (ADE) model to assess the impact of ketamine and R-ketamine on alcohol relapse across three European research centers. Ketamine (20 mg/kg) significantly reduced relapse, while R-ketamine showed efficacy only in females. A higher dose of R-ketamine (40 mg/kg) was also effective in males. These sex-dependent effects were linked to plasma R-ketamine levels, which were two-fold higher in female compared to male rats. Notably, R-ketamine demonstrated a lasting reduction in alcohol consumption without adverse effects. In conclusion, our preRCT demonstrates R-ketamine’s effectiveness in reducing alcohol relapse and supports translation to a clinical RCT that accounts for sex-dependent effects.
Year:
2025
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from induced pluripotent stem cells with the 5-HT2A receptor agonist psilocin - the psychoactive metabolite of psilocybin. We analyzed how exposure to psilocin affects 5-HT2A receptor localization, gene expression, neuronal morphology, synaptic markers and neuronal function. Upon exposure of human neurons to psilocin, we observed a decrease of cell surface-located 5-HT2A receptors first in the axonal- followed by the somatodendritic-compartment. Psilocin further provoked a 5-HT2A-R-mediated augmentation of BDNF abundance. Transcriptomic profiling identified gene expression signatures priming neurons to neuroplasticity. On a morphological level, psilocin induced enhanced neuronal complexity and increased expression of synaptic proteins, in particular in the postsynaptic-compartment. Consistently, we observed an increased excitability and enhanced synaptic network activity in neurons treated with psilocin. In conclusion, exposure of human neurons to psilocin might induces a state of enhanced neuronal plasticity which could explain why psilocin is beneficial in the treatment of neuropsychiatric disorders where synaptic dysfunctions are discussed.
Year:
2024
Patients with alcohol use disorder (AUD) who seek treatment show highly variable outcomes. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse. We reasoned here that prefrontal dysfunction, which underlies vulnerability to relapse, is evidenced by altered neuroelectric signatures and should be restored by pharmacological interventions that specifically target prefrontal dysfunction. To test this, we applied our recently developed biocompatible neuroprosthesis to measure prefrontal neural function in a well-established rat model of alcohol addiction and relapse. We monitored neural oscillations and event-related potentials in awake alcohol-dependent rats during abstinence and following treatment with psilocybin or LY379268, agonists of the serotonin 2A receptor (5-HT 2A R), and the metabotropic glutamate receptor 2 (mGluR2), that are known to reduce prefrontal dysfunction and relapse. Electrophysiological impairments in alcohol-dependent rats are reduced amplitudes of P1N1 and N1P2 components and attenuated event-related oscillatory activity. Psilocybin and LY379268 were able to restore these impairments. Furthermore, alcohol-dependent animals displayed a dominance in higher beta frequencies indicative of a state of hyperarousal that is prone to relapse, which particularly psilocybin was able to counteract. In summary, we provide prefrontal markers indicative of relapse and treatment response, especially for psychedelic drugs.
Year:
2024
Current treatments for alcohol use disorder (AUD) show large heterogeneity in response and thus limited effectiveness and high relapse rates. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse. We reasoned here that prefrontal dysfunction, which underlies vulnerability to relapse, is evidenced by altered neuroelectric signatures and should be restored by pharmacological interventions that specifically target prefrontal dysfunction. To test this, we applied our recently developed biocompatible neuroprosthesis to measure prefrontal neural function in a well-established rat model of alcohol addiction and relapse. We monitored neural oscillations and event-related potentials in awake alcohol-dependent rats during abstinence and following treatment with psilocybin or LY379268, agonists of the serotonin 2A receptor (5-HT 2A R) and the metabotropic glutamate receptor 2 (mGluR2), that are known to reduce prefrontal dysfunction and relapse. Electrophysiological impairments in alcohol-dependent rats are reduced amplitudes of P1N1 and N1P2 components and attenuated event-related oscillatory activity. Psilocybin and LY379268 were able to restore these impairments. Furthermore, alcohol-dependent animals displayed a dominance in higher beta frequencies indicative of a state of hyperarousal that is prone to relapse, which particularly psilocybin was able to counteract. In summary, we provide prefrontal markers indicative of relapse and treatment response, especially for psychedelic drugs.
Year:
2024
Background Understanding compulsive drinking behavior is key to improving outcomes in the treatment of addiction. In the present study, we investigated compulsive‐like drinking in alcohol‐addicted rats using the alcohol deprivation effect (ADE) model of relapse behavior, which involves repeated deprivation and reintroduction phases; the latter approximate relapse. Methods High‐resolution longitudinal drinking and locomotor data were measured while rats ( n = 30) underwent a four‐bottle (water, 5%, 10%, 20% alcohol v/v) free‐choice ADE paradigm. Alcohol bottles were adulterated with the bitter compound quinine during a reintroduction phase to test for compulsive behavior. We characterized how drinking and locomotor behavior during ADE + quinine differed from a regular ADE and how, at the individual level, behavioral parameters extracted from the regular ADE related to compulsive‐like drinking. Associations of drinking with locomotor activity were also examined. Results In the ADE with quinine, we observed reduced consumption of alcohol and a shift to preference for stronger alcohol. Quinine acted by decreasing both the access size and frequency of drinking of 5% alcohol while increasing the frequency of consumption of 20% alcohol. Preference for higher alcohol concentrations prior to the quinine challenge was associated with greater compulsive‐like drinking behavior; higher baseline consumption of 20% alcohol correlated with more drinking of quinine‐adulterated solutions while high frequency and amount of 5% alcohol consumption at baseline were correlated with being more strongly affected by quinine. Associations between locomotor activity and drinking behavior were observed at the hourly level. These associations reflected changing preferences across experimental phases. Conclusion Drinking patterns, and specifically solution preference, may offer insights into the presentation of compulsive‐like drinking. The findings provide a preclinical basis for observations from epidemiological studies that link higher risk and burden of alcohol‐related disease to stronger alcohol concentrations and encourage further translational studies to better understand the underlying mechanisms.
Year:
2022
Collaborators (16)
Michael Smolka
Professor of Systems Neuroscience
Technische Universität Dresden
Stefan Gutwinski
Charité - Universitätsmedizin Berlin
Eva Friedel
Freie Universität Berlin
Marcus W. Meinhardt
Central Institute of Mental Health
roberto ciccocioppo
University of Camerino
Lorenz Deserno
Associate Professor
University Hospital Würzburg
Florian Schlagenhauf
Professor
Charité - Universitätsmedizin Berlin
Philipp Koch
-
Markus Reichert
Heidelberg University
Franz Vollenweider
Chief Psychiatrist, Co-Director, Psychiatric Research Center
University of Zurich
Marcus Herdener
University of Zurich
Tanja Endrass
Technische Universität Dresden
Mickael Naassila
Membre sénior
Université de Picardie Jules Verne UFR de Pharmacie
Lea Zillich
University Medical Center Freiburg
Michael Rapp
Professor and Chair
University of Potsdam
Julia Ladewig
Group Leader
Central Institute of Mental Health
Make your next move.
Prepare your application
Review drafts before you send them.